Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

Author： Åsberg Anders   Rollag Halvor   Hartmann Anders  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.7, 2010-05, pp. : 1159-1166

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients

By Yu Marie A   Park Jeong M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 807-815

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic Profile of Ganciclovir After its Oral Administration and From its Prodrug, Valganciclovir, in Solid Organ Transplant Recipients

By Wiltshire Hugh  

Clinical Pharmacokinetics, Vol. 44, Iss. 5, 2005-01 ,pp. : 495-507

Adis International

Access to resources Recommend Favorite

Valganciclovir in Adult Solid Organ Transplant Recipients: Pharmacokinetic and Pharmacodynamic Characteristics and Clinical Interpretation of Plasma Concentration Measurements

By Perrottet Nancy  

Clinical Pharmacokinetics, Vol. 48, Iss. 6, 2009-06 ,pp. : 399-418

Adis International

Access to resources Recommend Favorite

Valganciclovir proves its value in CMV prevention

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 608, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

The Role of Sirolimus in the Prevention of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients

By LEBLANC   Jr KEITH G.   HUGHES MATTHEW P.   SHEEHAN DANIEL J.  

Dermatologic Surgery, Vol. 37, Iss. 6, 2011-06 ,pp. : 744-749

Elsevier

Access to resources Recommend Favorite